Gijsberta J. Van Londen, MD, MS | Authors

university physicians

2955 Ivy Road Suite 304

Articles

Breast Cancer: Never Too Young for a Functional Assessment?

September 12, 2012

Geriatricians would argue that biological age alone should not be used to estimate a patient's anticipated tolerance for cancer therapy.

Metabolic Effects of Hormone Deprivation Therapy: Weighing the Evidence

August 15, 2010

Adjuvant hormonal deprivation therapy is often administered long-term to patients with hormone receptor–positive cancers for primary prevention of breast cancer and secondary prevention of a recurrence.[1,2] This treatment modality is of particular importance to the elderly for two reasons: 1) the incidence of hormone-sensitive cancers (eg, prostate cancer and breast cancer) increases with age,[3] and 2) the systemic treatment regimens for elderly patients with hormone-responsive cancers are often limited to long-term hormonal deprivation therapy (HDT), most commonly androgen deprivation therapy for prostate cancer and aromatase inhibitor therapy for breast cancer, with chemotherapy often omitted.[2,4]